RANDOMIZED CONTROLLED TRIAL
Add like
Add dislike
Add to saved papers

Acute enhancement of lower-extremity dynamic strength and flexibility with whole-body vibration.

The purpose of this investigation was to examine the acute effects of whole-body vibration (WBV) on muscular strength, flexibility, and heart rate (HR). Twenty adults (10 men, 10 women) untrained to WBV participated in the study. All subjects completed assessment of lower-extremity isokinetic torque, flexibility, and HR immediately before and after 6 minutes of WBV and 6 minutes of leg cycling ergometry (CYL), in randomized order. During WBV, subjects stood upright on a vibration platform for a total of 6 minutes. Vibration frequency was gradually increased during the first minute to a frequency of 26 Hz, which was maintained for the remaining 5 minutes. During CYL, power output was gradually increased to 50 W during the first minute and maintained at that power output for the remaining 5 minutes. Lower-extremity flexibility was determined using the sit-and-reach box test. Peak and average isokinetic torque of knee extension and flexion were measured by means of a motor-driven dynamometer with velocity fixed at 120 degrees .s. Change scores for the outcome measures were compared between treatments using Student's paired t-tests. Analysis revealed significantly greater HR acceleration with CYL (24.7 bpm) than after WBV (15.8 bpm). The increase of sit-and-reach scores after WBV (4.7 cm) was statistically greater (p < 0.05) than after CYL (0.8 cm). After WBV, increases in peak and average isokinetic torque of knee extension, 7.7% and 9.6%, were statistically greater than after CYL (p < 0.05). Average torque of knee flexion also increased more with WBV (+7.8%) than with CYL (-1.5%) (p < 0.05). The findings of this study indicate that short-term WBV standing elicits acute enhancements of lower-extremity muscular torque and flexibility, suggesting the application of this technology as a preparatory activity before more intense exercise.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app